OverviewChartNewsTraderScreen

BVT Discount Zert BRM 27.09.2024/  DE000VM5UQG8  /

Frankfurt Zert./VONT
29/05/2024  13:53:44 Chg.-0.080 Bid13:53:44 Ask13:53:44 Underlying Strike price Expiration date Option type
36.510EUR -0.22% -
Bid Size: -		 -
Ask Size: -		 BRISTOL-MYERS SQUIBB... - - 27/09/2024 Call
GlobeNewswire 31/05 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire 30/05 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 24/05 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
GlobeNewswire 23/05 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 23/05 Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire 22/05 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 22/05 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 16/05 CytomX Therapeutics Announces New Employment Inducement Grants
GlobeNewswire 15/05 Lantheus Announces Executive Appointments to Accelerate Innovation
GlobeNewswire 14/05 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire 14/05 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire 13/05 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 08/05 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08/05 Immunocore reports first quarter financial results and provides a business update
GlobeNewswire 07/05 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire 02/05 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire 01/05 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
GlobeNewswire 01/05 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire 30/04 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
GlobeNewswire 30/04 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...
GlobeNewswire 25/04 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...
GlobeNewswire 25/04 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...
GlobeNewswire 25/04 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire 22/04 ArriVent Appoints Kristine Peterson to its Board of Directors
GlobeNewswire 08/04 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...